CRISPR QC Assay

About Stilla Technologies

Stilla Technologies, founded in 2016 and based in Paris, is a leader in multiplex digital PCR technology. The company's core innovation is the Nio® platform, which offers 7-color detection, continuous loading, and high sample throughput, addressing key limitations in traditional dPCR and qPCR. Its technology is applied in critical areas such as cancer mutation detection, CRISPR quality control, and viral vector analytics, serving academic, clinical, and biopharmaceutical customers. In 2024, Stilla Technologies was acquired by Bio-Rad Laboratories, significantly enhancing its global commercial reach and resources.

Therapeutic Areas